Optimal ARB Selection for Blood Pressure Management

Clinical Context and Guideline Recommendations

The American Heart Association recommends candesartan and valsartan as preferred ARBs for heart failure with reduced ejection fraction, as they have proven mortality and hospitalization reduction benefits 1
The American College of Cardiology suggests telmisartan and irbesartan for superior 24-hour blood pressure control, making them preferred choices when sustained blood pressure reduction is the priority 1
The American Diabetes Association recommends ACE inhibitors or ARBs at maximum tolerated doses as first-line treatment for patients with diabetes and urinary albumin-to-creatinine ratio ≥300 mg/g (Grade A) or 30-299 mg/g (Grade B) 2, 3
The National Kidney Foundation recommends losartan for diabetic nephropathy with elevated serum creatinine and proteinuria in type 2 diabetes, reducing progression to doubling of serum creatinine or end-stage renal disease 1

The American College of Cardiology recommends prompt initiation of pharmacologic therapy in addition to lifestyle modifications for patients with confirmed blood pressure ≥140/90 mmHg 2
The American Heart Association suggests initiating two drugs or a single-pill combination immediately for blood pressure ≥160/100 mmHg 2
The American Diabetes Association recommends ARBs as first-line treatment for hypertension in patients with coronary artery disease, chronic kidney disease, heart failure, or diabetes 2, 3, 4

The National Kidney Foundation recommends rechecking blood pressure, serum creatinine, and potassium within 1-2 weeks of ARB initiation, with high-risk patients requiring closer surveillance 1
The American College of Cardiology suggests monitoring serum creatinine/eGFR and potassium at least annually for patients on ARBs, diuretics, or ACE inhibitors 2, 3
The American Heart Association recommends maximum tolerated doses of ARBs to achieve guideline-recommended blood pressure targets of <130/80 mmHg 2, 5
The American Diabetes Association recommends against using low-dose ARB monotherapy when combination therapy is indicated, and against delaying treatment intensification 5, 4